Suppr超能文献

双膦酸盐在羟基磷灰石上结合的结构要求:双膦酸盐偏酯的核磁共振研究

Structural requirements for bisphosphonate binding on hydroxyapatite: NMR study of bisphosphonate partial esters.

作者信息

Puljula Elina, Turhanen Petri, Vepsäläinen Jouko, Monteil Maelle, Lecouvey Marc, Weisell Janne

机构信息

School of Pharmacy, University of Eastern Finland , Biocenter Kuopio, PL-1627, 70210 Kuopio, Finland.

Université Paris 13, Sorbonne Paris Cité, CSPBAT, CNRS UMR 7244 , 74, Rue Marcel Cachin, F-93017 Bobigny, France.

出版信息

ACS Med Chem Lett. 2015 Feb 21;6(4):397-401. doi: 10.1021/ml5004603. eCollection 2015 Apr 9.

Abstract

Eighteen different bisphosphonates, including four clinically used bisphosphonate acids and their phosphoesters, were studied to evaluate how the bisphosphonate structure affects binding to bone. Bisphosphonates with weak bone affinity, such as clodronate, could not bind to hydroxyapatite after the addition of one ester group. Medronate retained its ability to bind after the addition of one ester group, and hydroxy-bisphosphonates could bind even after the addition of two ester groups. Thus, several bisphosphonate esters are clearly bone binding compounds. The following conclusions about bisphosphonate binding emerge: (1) a hydroxyl group in the geminal carbon takes part in the binding process and increases the bisphosphonate's ability to bind to bone; (2) the bisphosphonate's ability to bind decreases when the amount of ester groups increases; and (3) the location of the ester groups affects the bisphosphonate's binding ability.

摘要

研究了18种不同的双膦酸盐,包括4种临床使用的双膦酸及其磷酸酯,以评估双膦酸盐结构如何影响与骨的结合。骨亲和力较弱的双膦酸盐,如氯膦酸盐,在添加一个酯基后无法与羟基磷灰石结合。甲膦酸盐在添加一个酯基后仍保留其结合能力,而羟基双膦酸盐即使在添加两个酯基后仍能结合。因此,几种双膦酸酯显然是骨结合化合物。关于双膦酸盐结合得出以下结论:(1)偕碳中的羟基参与结合过程并增加双膦酸盐与骨结合的能力;(2)当酯基数量增加时,双膦酸盐的结合能力降低;(3)酯基的位置影响双膦酸盐的结合能力。

相似文献

1
Structural requirements for bisphosphonate binding on hydroxyapatite: NMR study of bisphosphonate partial esters.
ACS Med Chem Lett. 2015 Feb 21;6(4):397-401. doi: 10.1021/ml5004603. eCollection 2015 Apr 9.
2
The Effects of Various Food Products on Bisphosphonate's Availability.
Pharmaceutics. 2022 Mar 27;14(4):717. doi: 10.3390/pharmaceutics14040717.
3
Comparative appraisal of clodronate, aspirin and dexamethasone as agents reducing alendronate-induced inflammation in a murine model.
Basic Clin Pharmacol Toxicol. 2005 Oct;97(4):222-9. doi: 10.1111/j.1742-7843.2005.pto_138.x.
4
Synthetic Hydroxyapatite Inhibits Bisphosphonate Toxicity to the Oral Mucosa In Vitro.
Materials (Basel). 2020 May 1;13(9):2086. doi: 10.3390/ma13092086.
5
Bisphosphonates: from the laboratory to the clinic and back again.
Bone. 1999 Jul;25(1):97-106. doi: 10.1016/s8756-3282(99)00116-7.
6
The relationship between the chemistry and biological activity of the bisphosphonates.
Bone. 2011 Jul;49(1):20-33. doi: 10.1016/j.bone.2011.03.774. Epub 2011 Apr 9.
7
Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite.
Bone. 2006 May;38(5):617-27. doi: 10.1016/j.bone.2005.05.003. Epub 2005 Jul 20.
8
Bisphosphonates for breast cancer.
Cochrane Database Syst Rev. 2005 Jul 20(3):CD003474. doi: 10.1002/14651858.CD003474.pub2.
9
Are all bisphosphonates the same? Potential reasons for clinical differences: a perspective.
J Womens Health (Larchmt). 2010 Apr;19(4):719-27. doi: 10.1089/jwh.2008.1196.
10
Bisphosphonates for breast cancer.
Cochrane Database Syst Rev. 2002(1):CD003474. doi: 10.1002/14651858.CD003474.

引用本文的文献

5
Research advances of nanomaterials for the acceleration of fracture healing.
Bioact Mater. 2023 Aug 27;31:368-394. doi: 10.1016/j.bioactmat.2023.08.016. eCollection 2024 Jan.
6
Bisphosphonates as Potential Inhibitors of Calcification in Bioprosthetic Heart Valves (Review).
Sovrem Tekhnologii Med. 2022;14(2):68-78. doi: 10.17691/stm2022.14.2.07. Epub 2022 Mar 28.
7
Hydroxy- and Amino-Phosphonates and -Bisphosphonates: Synthetic Methods and Their Biological Applications.
Front Chem. 2022 Jun 1;10:890696. doi: 10.3389/fchem.2022.890696. eCollection 2022.
8
Prodrugs of pyrophosphates and bisphosphonates: disguising phosphorus oxyanions.
RSC Med Chem. 2022 Mar 1;13(4):375-391. doi: 10.1039/d1md00297j. eCollection 2022 Apr 20.
10
One-Pot Synthesis of Phosphinylphosphonate Derivatives and Their Anti-Tumor Evaluations.
Molecules. 2021 Dec 15;26(24):7609. doi: 10.3390/molecules26247609.

本文引用的文献

1
Bisphosphonate prodrugs: synthesis and biological evaluation in HuH7 hepatocarcinoma cells.
Eur J Med Chem. 2014 Apr 22;77:56-64. doi: 10.1016/j.ejmech.2014.02.054. Epub 2014 Feb 23.
3
Inhibitory effect of novel S,N-bisphosphonates on some carcinoma cell lines, osteoarthritis, and chronic inflammation.
Eur J Med Chem. 2012 May;51:239-49. doi: 10.1016/j.ejmech.2012.02.047. Epub 2012 Mar 6.
4
Bisphosphonamidate clodronate prodrug exhibits potent anticancer activity in non-small-cell lung cancer cells.
J Med Chem. 2011 Oct 13;54(19):6647-56. doi: 10.1021/jm200521a. Epub 2011 Sep 9.
5
Pharmacology of bisphosphonates.
Bone. 2011 Jul;49(1):42-9. doi: 10.1016/j.bone.2011.01.014. Epub 2011 Jan 31.
6
Molecular interactions between zoledronic acid and bone: An in vitro Raman microspectroscopic study.
Bone. 2010 Nov;47(5):895-904. doi: 10.1016/j.bone.2010.07.018. Epub 2010 Jul 23.
7
Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class.
Bone. 2011 Jan;48(1):71-9. doi: 10.1016/j.bone.2010.07.016. Epub 2010 Jul 22.
8
Bisphosphonate protonation states, conformations, and dynamics on bone mineral probed by solid-state NMR without isotope enrichment.
Eur J Pharm Biopharm. 2010 Sep;76(1):120-6. doi: 10.1016/j.ejpb.2010.05.013. Epub 2010 Jun 8.
9
An in vitro assay to measure targeted drug delivery to bone mineral.
ChemMedChem. 2010 May 3;5(5):770-6. doi: 10.1002/cmdc.201000016.
10
Differences between bisphosphonates in binding affinities for hydroxyapatite.
J Biomed Mater Res B Appl Biomater. 2010 Jan;92(1):149-55. doi: 10.1002/jbm.b.31500.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验